China CDC weekly · 2026
Financial Feasibility of BPaL(M) Under Pretomanid Price Scenarios - China, 2023-2024.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ren Jingjuan, Wang Ni, Zhu He, Nie Wenjuan, Sun Feng, Xiong Yu, Fu Liang, Luo Hui, Cheng Shiming, Zhao Yanlin, Huang Fei
Аннотация
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: The BPaL(M) regimen is a World Health Organization (WHO)-endorsed, all-oral, shorter treatment for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) recently approved in China; however, its large-scale implementation depends on affordability and sustainability within the national health insurance system.
WHAT IS ADDED BY THIS REPORT?: This study identifies 26,000 Chinese Yuan (CNY) per course as an approximate break-even pretomanid price for health insurance reimbursement in China. Lower prices can generate savings for both insurers and patients.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: Pretomanid price negotiations should be combined with reimbursement and financial protection policies to support equitable scale-up of BPaL(M).
WHAT IS ADDED BY THIS REPORT?: This study identifies 26,000 Chinese Yuan (CNY) per course as an approximate break-even pretomanid price for health insurance reimbursement in China. Lower prices can generate savings for both insurers and patients.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: Pretomanid price negotiations should be combined with reimbursement and financial protection policies to support equitable scale-up of BPaL(M).